By , SAO PAULO/FRANKFURT (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about safety of the clinical trial.”AstraZeneca declined to comment immediately.A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine,...…By , SAO PAULO/FRANKFURT (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about safety of the clinical trial.”AstraZeneca declined to comment immediately.A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine,...WW…

By , SAO PAULO/FRANKFURT (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about safety of the clinical trial.”AstraZeneca declined to comment immediately.A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine,...…By , SAO PAULO/FRANKFURT (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue.Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about safety of the clinical trial.”AstraZeneca declined to comment immediately.A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine,...WW…